IMC P115C
Alternative Names: IMC-P115CLatest Information Update: 26 Dec 2024
Price :
$50 *
At a glance
- Originator Immunocore
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins; Single-domain antibodies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 23 Dec 2024 Phase-I clinical trials in Solid tumours (Late-stage disease) in United Kingdom (Parenteral)
- 04 Oct 2024 Immunocore plans a phase I trial for Solid tumours (Parenteral), in first half of 2025 (Immunocore pipeline, October 2024)
- 28 Feb 2024 Immunocore plans to file an CTA application for Solid tumours in the middle of 2024 (Immunocore pipeline, September 2023)